Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:1 Issue:3 Number:189 ISSN#:2563-5476
ACE Report #167
Ace Report Cover Arthroplasty

Apixiban more effective than enoxaparin for prevention of postoperative thromboembolism

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial

Lancet. 2010 Mar 6;375(9717):807-15.

Contributing Authors: MR Lassen GE Raskob A Gallus G Pineo D Chen P Hornick ADVANCE-2 investigatorsCollaborators (181)

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


3057 patients scheduled for an elective unilateral or same-day bilateral total knee replacement were randomized to the drug used in prevention of venous thromboembolism, either oral apixiban or subcutaneous enoxaparin. 60 days after the final dose apixiban when compared to enoxaparin was found to be more effective in preventing thrombosis events, had lesser bleeding risks, and had the convenience ...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.